COMMUNIQUÉS West-GlobeNewswire

MMI Receives IDE Approval from FDA for First Robotic Microsurgical Study in Alzheimer’s Patients
05/11/2025
First-of-its-kind study represents the potential for robotic-enabled microsurgical intervention for neurodegenerative diseases, including Alzheimer’s JACKSONVILLE, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- MMI (Medical [...]
SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025
05/11/2025
DENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and [...]
FORM 8.1(a) & (b) - Avadel Pharmaceuticals plc
05/11/2025
U.K. DISCLOSURE, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ap9 FORM 8.1(a) & (b) (Opening Position Disclosure) IRISH TAKEOVER PANEL OPENING POSITION DISCLOSURE UNDER RULE 8.1(a) AND (b) OF THE IRISH TAKEOVER PANEL ACT, 1997 [...]
Idorsia to present new aprocitentan insights at ASN Kidney Week & AHA Scientific Sessions
05/11/2025
New analysis confirms reductions in blood pressure and albuminuria by aprocitentan in patients with true resistant hypertension and high cardiovascular risk – including chronic kidney disease Allschwil, Switzerland – [...]
beyond|AESTHETICS Celebrates 10 Years of Excellence with Grand Holiday Event
05/11/2025
Camarillo, CA, Nov. 05, 2025 (GLOBE NEWSWIRE) -- beyond|AESTHETICS , a leader in the aesthetics industry, is thrilled to announce its 10 Year Anniversary Holiday Event, a spectacular celebration marking a decade of [...]
VALNEVA Declaration of shares and voting rights: October 31, 2025
05/11/2025
VALNEVA Declaration of shares and voting rights October 31, 2025 __________________________________________________________________________________________ Company name: VALNEVA Registered office: 6 rue Alain Bombard, [...]
VALNEVA Déclaration d’actions et de droits de vote : 31 octobre 2025
05/11/2025
VALNEVA Déclaration d’actions et de droits de vote 31 octobre 2025 __________________________________________________________________________________________ Dénomination sociale : VALNEVA Adresse du siège social : 6 [...]
Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results
05/11/2025
ORIGIN 3 trial primary endpoint results for Atacicept in IgA nephropathy (IgAN) selected as a featured late-breaking oral presentation during opening plenary session of American Society of Nephrology (ASN) Kidney Week [...]
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
05/11/2025
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of [...]
Rezolute to Host Virtual Investor Event on Ersodetug Development Program
05/11/2025
Webcast scheduled for Monday, November 10 at 12:00 pm EST REDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on [...]
Crescent Biopharma to Present at November Investor Conferences
05/11/2025
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Crescent Biopharma , Inc. (“Crescent” or the “Company”) (Nasdaq: CBIO), a biotechnology company dedicated to rapidly advancing the next wave of therapies for cancer [...]
Minerva Neurosciences Reports Third Quarter 2025 Financial Results and Business Updates
05/11/2025
BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) [...]
Altimmune to Participate in Two Upcoming Investor Conferences
05/11/2025
GAITHERSBURG, Md., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, [...]
Compass Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
05/11/2025
Based on a continuing trend of decreased mortality in the ongoing Phase 2/3 COMPANION-002 study of tovecimig (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC), the analyses of [...]
MediWound to Report Third Quarter 2025 Financial Results
05/11/2025
MediWound to Report Third Quarter 2025 Financial Results Conference call and webcast scheduled for Thursday, November 20 at 8:30 a.m. Eastern Time YAVNE, Israel, November 5, 2025 -- MediWound Ltd. (Nasdaq: MDWD) (the “ [...]
Lexeo Therapeutics Reports Third Quarter 2025 Financial Results and Operational Highlights
05/11/2025
FDA open to pooling data from ongoing Phase I/II studies of LX2006 with data from pivotal trial, and to earlier co-primary endpoint assessment, to support a Biologics License Application FDA approved comparability [...]
Curonix Strengthens Executive Leadership with Appointment of Leading Medical Device Executive Russell Fleeger as Chief Financial Officer to Drive Next Stage of Growth
05/11/2025
POMPANO BEACH, Fla., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Curonix LLC (“Curonix” or the “Company”), a medical technology company dedicated to developing and commercializing innovative therapies to relieve chronic pain, [...]
MannKind Corporation Reports Third Quarter 2025 Financial Results and Provides Business Update
05/11/2025
Conference call today at 9:00 am ET Q3 2025 revenues of $82.1M, +17% v. Q3 2024 YTD 2025 revenues of $237.0M, +14% v. YTD 2024 Completed acquisition of scPharmaceuticals on October 7, accelerating MannKind’s revenue [...]
LENZ Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
05/11/2025
VIZZ TM (aceclidine ophthalmic solution) 1.44% received FDA approval for the treatment of presbyopia Commercial product launch initiated in October 2025 with broad product availability in mid-Q4 2025 Over 2,500 ECPs [...]

Pages